Table 2.
References for cost effectiveness thresholds
| Level of value | ICER (per QALY gained) | USA | UK | Germany | Italy |
|---|---|---|---|---|---|
| Official threshold | None | £20 000–£30 000 | None |
None Proposed €25 000–40 000 |
|
| High value/highly cost-effective | Less than GDP per capita | <$50 000 | £33 100 | €41 500 | €29 600 |
| Intermediate value/cost-effective | Between 1 and 3 times GDP per capita | $50 000 to <$150 000 | £33 100 to <£99 400 | €41 500 to <€124 500 | €29 600 to <€88 900 |
| Low value/not cost-effective | Greater than 3 × GDP per capita | >$150 000 | >£99 400 | >€124 500 | >€88 900 |
US values based on ACC/AHA statement on cost/value methodology.29
UK values based on National Institute for Health and Care Excellence methods and WHO guidance.
Italy values based on Italian Health Economics Association (AIES) recommendation and WHO guidance.
ACC/AHA, American College of Cardiology/American Heart Association; GDP, Gross Domestic Product; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life-year; WHO, World Health Organization.